Your browser is no longer supported. Please, upgrade your browser.
Settings
NKTR Nektar Therapeutics daily Stock Chart
NKTR [NASD]
Nektar Therapeutics
IndexS&P 500 P/E10.52 EPS (ttm)3.96 Insider Own1.00% Shs Outstand172.70M Perf Week-7.13%
Market Cap7.20B Forward P/E- EPS next Y-2.00 Insider Trans-11.06% Shs Float171.60M Perf Month-6.57%
Income745.70M PEG- EPS next Q-0.54 Inst Own92.60% Short Float11.50% Perf Quarter11.62%
Sales1.25B P/S5.76 EPS this Y188.30% Inst Trans-1.54% Short Ratio9.62 Perf Half Y-28.88%
Book/sh10.37 P/B4.02 EPS next Y-151.70% ROA53.60% Target Price78.89 Perf Year-50.37%
Cash/sh8.22 P/C5.07 EPS next 5Y-7.30% ROE78.60% 52W Range29.22 - 111.36 Perf YTD26.83%
Dividend- P/FCF9.63 EPS past 5Y21.50% ROI56.40% 52W High-62.56% Beta3.14
Dividend %- Quick Ratio13.80 Sales past 5Y30.50% Gross Margin97.90% 52W Low42.67% ATR2.13
Employees509 Current Ratio13.90 Sales Q/Q-81.80% Oper. Margin61.20% RSI (14)48.41 Volatility5.48% 4.31%
OptionableYes Debt/Eq0.00 EPS Q/Q-248.70% Profit Margin59.70% Rel Volume1.41 Prev Close42.62
ShortableYes LT Debt/Eq0.14 EarningsFeb 28 AMC Payout0.00% Avg Volume2.05M Price41.69
Recom1.80 SMA20-4.54% SMA505.64% SMA200-19.64% Volume2,891,633 Change-2.18%
Dec-13-18Initiated Goldman Buy $62
Jun-11-18Downgrade H.C. Wainwright Buy → Neutral $54
Jun-04-18Reiterated H.C. Wainwright Buy $125 → $97
Apr-20-18Initiated Seaport Global Securities Buy $120
Apr-13-18Resumed Piper Jaffray Overweight $125
Apr-06-18Reiterated Mizuho Buy $89 → $103
Apr-02-18Resumed H.C. Wainwright Buy $125
Mar-02-18Reiterated Canaccord Genuity Buy $80 → $94
Jan-22-18Reiterated Mizuho Buy $45 → $89
Nov-13-17Reiterated Mizuho Buy $30 → $45
Nov-13-17Reiterated Canaccord Genuity Buy $35 → $50
Nov-09-17Initiated Canaccord Genuity Buy $35
Aug-17-17Initiated Evercore ISI In-line $20
Aug-07-17Initiated H.C. Wainwright Buy $31
Mar-20-17Reiterated ROTH Capital Buy $23 → $31
Nov-08-16Initiated Aegis Capital Buy
Sep-30-16Resumed Brean Capital Buy
Jan-07-16Reiterated Piper Jaffray Overweight $16 → $20
Mar-18-15Reiterated ROTH Capital Buy $21 → $19
Mar-18-15Reiterated Brean Capital Buy $20 → $17
Feb-15-19 03:15PM  Nektar, Bristol combo drug shows signs of tumor reduction in bladder cancer patients Reuters
03:15PM  Clinical Data Presented from PIVOT-02 Study of Bempegaldesleukin (NKTR-214) with Nivolumab in Metastatic Urothelial Carcinoma Patients at the 2019 ASCO Genitourinary Cancers Symposium PR Newswire
07:35AM  Factors of Influence in 2019, Key Indicators and Opportunity within BCE, Nektar Therapeutics, Hormel Foods, Enanta Pharmaceuticals, MongoDB, and Regal Beloit New Research Emphasizes Economic Growth GlobeNewswire
Feb-14-19 05:24AM  8 Stocks That Can Lead in a 'Micro-Driven' Market Investopedia
Feb-12-19 03:02PM  9 U.S. Stocks That Are Coming to Life Again InvestorPlace -8.82%
08:04AM  The Daily Biotech Pulse: NASH Disappointment For Gilead, Xeris To Offer Shares Benzinga
Feb-11-19 05:14PM  Nektar Therapeutics to Webcast Conference Call with Urothelial Cancer Specialist for Analysts & Investors at the 2019 ASCO Genitourinary Cancers Symposium PR Newswire
01:49PM  Why Nektar Therapeutics Stock Gained 29% in January Motley Fool
Feb-05-19 02:25PM  Mizuho's 9 Best Biotech Stocks to Buy for 2019 Kiplinger
Jan-27-19 11:05AM  5 "Strong Buy" Stock Picks for 2019 (That Crashed in 2018) Kiplinger
Jan-26-19 10:05AM  Is Bristol-Myers Squibb a Bargain Now? Motley Fool
Jan-15-19 07:11AM  These beaten-down stocks are expected to roar back in 2019 MarketWatch +7.23%
Jan-14-19 08:46PM  Here's Why Nektar Therapeutics Gave Back 45% in 2018 Motley Fool
Jan-08-19 05:28PM  Here's Why Nektar Therapeutics Surged Today Motley Fool +11.09%
10:03AM  Top Gainers: Union Pacific, Motorcar Parts, Nektar Rally Into Close Investing.com
Jan-03-19 07:00AM  Today's Research Reports on Trending Tickers: Celgene and Nektar Therapeutics ACCESSWIRE -7.71%
07:00AM  ImaginAb Announces Immuno-Oncology License and Clinical Trial Collaboration with Nektar Therapeutics PR Newswire
Dec-31-18 12:50PM  DEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
10:09AM  CLASS ACTION UPDATE for NKTR, FIT, WBT and XRAY: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
10:00AM  FINAL DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Nektar Therapeutics, Inc. (NKTR) and Lead Plaintiff Deadline - December 31, 2018 GlobeNewswire
Dec-30-18 09:25PM  FINAL DEADLINE TOMORROW: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Reminds Investors with Losses in Excess of $250,000 to Contact the Firm ACCESSWIRE
Dec-29-18 08:00AM  NKTR FINAL DEADLINE: Rosen Law Firm Reminds Nektar Therapeutics Investors of Important December 31 Deadline in Class Action NKTR GlobeNewswire
Dec-28-18 05:07PM  3 Top Biotech Stocks to Buy Right Now Motley Fool
04:55PM  BioXcel Surges on Fast Track Designation to Agitation Drug Zacks
10:00AM  Pawar Law Group Reminds of Deadline in Securities Class Action Lawsuit Against Nektar Therapeutics - NKTR ACCESSWIRE
09:02AM  DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Nektar Therapeutics, Inc. (NKTR) and Lead Plaintiff Deadline - December 31, 2018 ACCESSWIRE
07:00AM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of COST, NKTR, FIT and RBBN GlobeNewswire
Dec-27-18 09:55PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Nektar Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline NKTR ACCESSWIRE
12:02PM  MONDAY DEADLINE: The Schall Law Firm Announces it is Investigating Claims Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
09:59AM  SHAREHOLDER ALERT: ALGN NKTR FIT RBBN: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines GlobeNewswire
08:30AM  Nektar Therapeutics' President and CEO, Howard Robin, To Present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, CA PR Newswire
Dec-26-18 01:45PM  IMPORTANT DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Reminds Investors with Losses in Excess of $250,000 to Contact the Firm ACCESSWIRE +7.72%
01:01PM  CLASS ACTION UPDATE for IGCC, NKTR and FIT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
10:00AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Nektar Therapeutics, Inc. (NKTR) and Lead Plaintiff Deadline - December 31, 2018 GlobeNewswire
09:38AM  KESSLER TOPAZ MELTZER & CHECK, LLP: Final Deadline Reminder for NEKTAR THERAPEUTICS Investors NKTR GlobeNewswire
Dec-25-18 10:07AM  Is Nektar Therapeuticss (NASDAQ:NKTR) CEO Pay Justified? Simply Wall St.
Dec-24-18 10:00AM  DEADLINE NEXT WEEK: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
09:01AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Nektar Therapeutics, Inc. (NKTR) and Lead Plaintiff Deadline - December 31, 2018 ACCESSWIRE
Dec-23-18 09:10PM  DECEMBER DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Reminds Investors with Losses in Excess of $250,000 to Contact the Firm ACCESSWIRE
02:00PM  IGCC, NKTR DOUBLE ALERT: Pawar Law Group Reminds Investors of Class Action Deadlines in IGCC NKTR ACCESSWIRE
01:00PM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of APOG, IGCC, NKTR and FIT GlobeNewswire
Dec-21-18 01:03PM  SHAREHOLDER ALERT: COST NKTR TX APHA: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines GlobeNewswire -6.16%
12:35PM  IMPORTANT DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Reminds Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
10:18AM  INVESTOR REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Securities Fraud Class Action Lawsuit Filed Against Nektar Therapeutics Business Wire
Dec-20-18 03:50PM  NKTR DEADLINE ALERT: Rosen Law Firm Reminds Nektar Therapeutics Investors of Important Deadline in Class Action NKTR GlobeNewswire
12:35PM  DECEMBER 31 DEADLINE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Reminds Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
11:07AM  CLASS ACTION UPDATE for DY, NKTR and TX: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
10:00AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Nektar Therapeutics, Inc. (NKTR) and Lead Plaintiff Deadline - December 31, 2018 GlobeNewswire
Dec-19-18 01:34PM  IMPORTANT DECEMBER DEADLINE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Reminds Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
11:50AM  SHAREHOLDER ALERT: COST NKTR WBT SYF PPDF BA XPO TDOC: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines GlobeNewswire
07:00AM  Today's Research Reports on Trending Tickers: Nektar Therapeutics and Aduro BioTech ACCESSWIRE
Dec-18-18 05:20PM  FINAL DEADLINE APPROACHING: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Reminds Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
04:50PM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of COST, NKTR, GSKY, RBBN (SONS) and MGI GlobeNewswire
09:43AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Nektar Therapeutics, Inc. (NKTR) and Lead Plaintiff Deadline - December 31, 2018 ACCESSWIRE
Dec-17-18 03:20PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Nektar Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - NKTR ACCESSWIRE -6.44%
01:00PM  CLASS ACTION UPDATE for IGCC, NKTR and FIT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
11:49AM  END OF MONTH DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
08:42AM  Kessler Topaz Meltzer & Check, LLP - Important Deadline Reminder for Nektar Therapeutics Investors GlobeNewswire
Dec-16-18 12:00PM  SHAREHOLDER ALERT: APOG NKTR SYF GSKY RBBN (SONS) MGI NSANY CURO LOMA: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines GlobeNewswire
Dec-14-18 05:05PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Nektar Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline NKTR GlobeNewswire
03:55PM  INVESTOR ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Reminds Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
01:34PM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of CWH, HON, DY, ALGN and NKTR GlobeNewswire
09:13AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Nektar Therapeutics, Inc. (NKTR) & Lead Plaintiff Deadline - December 31, 2018 ACCESSWIRE
Dec-13-18 09:00PM  IMPORTANT DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Reminds Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
02:52PM  CLASS ACTION UPDATE for IGCC, NKTR and SYF: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
12:19AM  Nektar Therapeutics (NKTR): Are Hedge Funds Right About This Stock? Insider Monkey
Dec-12-18 07:57PM  Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Jianpu, Nektar, Honeywell, and Fitbit and Encourages Investors to Contact the Firm GlobeNewswire
07:15PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Nektar Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline NKTR ACCESSWIRE
06:48PM  Deadline Alert: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit against Nektar Therapeutics, Inc. Business Wire
04:30PM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Nektar Therapeutics To Contact The Firm ACCESSWIRE
02:06PM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of APOG, IGCC, NKTR, TSRO and APHA GlobeNewswire
02:06PM  8 Stocks With High Sharpe Ratios to Stomach Volatility Investopedia
01:25PM  SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Reminds Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
12:30PM  NKTR NOTICE: Rosen Law Firm Reminds Nektar Therapeutics Investors of Important Deadline in Class Action Seeking Investor Losses NKTR GlobeNewswire
10:00AM  SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Nektar Therapeutics, Inc. (NKTR) & Lead Plaintiff Deadline - December 31, 2018 GlobeNewswire
Dec-11-18 06:43PM  Glancy Prongay & Murray LLP Reminds Investors of the Deadline in the Class Action Lawsuit Against Nektar Therapeutics, Inc. Business Wire
04:54PM  SHAREHOLDER ALERT: COST NKTR FIT RBBN SONS MGI ATUS CMCM: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines GlobeNewswire
12:47PM  SHAREHOLDER DEADLINE NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Reminds Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
12:31PM  CLASS ACTION UPDATE for NKTR, MGI and ATUS: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
Dec-10-18 05:57PM  Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Nektar Therapeutics, Inc. Investors Business Wire
04:40PM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of NKTR, GSKY, RBBN (SONS), MDR and TX GlobeNewswire
03:40PM  UPCOMING DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
03:08PM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Nektar Therapeutics To Contact The Firm GlobeNewswire
11:18AM  Kessler Topaz Meltzer & Check, LLP - Important Deadline Reminder for Nektar Therapeutics Investors GlobeNewswire
11:15AM  NKTR REMINDER: Pawar Law Group Reminds of Deadline in Securities Class Action Lawsuit Against Nektar Therapeutics - NKTR ACCESSWIRE
Dec-09-18 10:23AM  SHAREHOLDER ALERT: DY NKTR GSKY ATUS TX BA APHA: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines GlobeNewswire
Dec-07-18 04:23PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Nektar Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline NKTR GlobeNewswire
03:14PM  CLASS ACTION UPDATE for IGCC, NKTR, FIT and SYF: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
02:17PM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of APOG, TRVN, GOOG, NKTR and RYAAY GlobeNewswire
11:15AM  IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Reminds Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
Dec-06-18 08:00PM  Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Nektar Therapeutics, Inc. Investors (NKTR) Business Wire
03:00PM  SHAREHOLDER ALERT: JT TRVN HTHT OZK NKTR FIT GSKY ATUS PPDF MAR: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines GlobeNewswire
11:55AM  Pawar Law Group Announces a Securities Class Action Lawsuit Against Nektar Therapeutics - NKTR ACCESSWIRE
11:43AM  CLASS ACTION UPDATE for TRVN, HTHT and NKTR: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
Dec-05-18 06:30PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Nektar Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline NKTR ACCESSWIRE
03:05PM  IMPORTANT SHAREHOLDER NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Reminds Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
02:48PM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of HTHT, DY, ALGN, NKTR and SYF GlobeNewswire
Dec-04-18 06:41PM  NKTR ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Nektar Therapeutics; Important Deadline - NKTR PR Newswire -6.24%
Dec-03-18 03:25PM  SHAREHOLDER ALERT: JT TRVN GOOG CWH OZK NKTR SYF AQUA GSKY: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines GlobeNewswire
03:02PM  INVESTOR NOTICE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
Nektar Therapeutics, a research-based biopharmaceutical company, discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology. It is also developing MOVANTIK for opioid-induced constipation in adult patients with chronic non-cancer pain, and who have an inadequate response to laxatives; ADYNOVATE for hemophilia A; Somavert to treat acromegaly; and Neulasta for treating neutropenia. In addition, the company develops PEG-INTRON for the treatment of hepatitis-C; Macugen for age-related macular degeneration; CIMZIA to treat rheumatoid arthritis, Crohn's disease, and psoriasis/ankylosing spondylitis; and MIRCERA for anemia related to chronic kidney disease in patients on and not on dialysis. Further, it is developing SEMPRANA to treat migraine; dapirolizumab pegol for systemic lupus erythematosus; PEGPH20 for ancreatic, non-small cell lung cancer, and other tumor types; and longer-acting blood clotting proteins for hemophilia. The company has collaboration agreement with AstraZeneca AB, Shire plc, Pfizer Inc., Amgen Inc., Merck & Co., Inc., Valeant Pharmaceuticals International, Inc., UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Allergan, Inc., Halozyme Therapeutics, Inc., Baxalta Incorporated, Bristol-Myers Squibb Company, and Takeda Pharmaceutical Company Limited. The company was founded in 1990 and is headquartered in San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Thomsen Jillian B.SVP & Chief Accounting OfficerFeb 04Option Exercise10.6916,119172,312184,318Feb 06 07:17 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerFeb 04Sale42.1616,119679,577168,199Feb 06 07:17 PM
Nicholson JohnSVP & Chief Operating OfficerJan 28Option Exercise10.6963,000673,470237,477Jan 30 06:02 PM
Nicholson JohnSVP & Chief Operating OfficerJan 28Sale42.8263,0002,697,660174,477Jan 30 06:02 PM
Hora ManinderSVP Pharma Dev & Mfg OpsNov 16Sale38.254,694179,54681,029Nov 19 06:12 PM
ROBIN HOWARD WPresident & CEONov 16Sale38.2515,326586,220249,141Nov 19 06:14 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerNov 16Sale38.254,016153,612157,249Nov 19 06:15 PM
Nicholson JohnSVP & Chief Operating OfficerNov 16Sale38.255,982228,812174,477Nov 19 06:14 PM
Labrucherie Gil MSVP & Chief Financial OfficerNov 16Sale38.256,515249,199106,544Nov 19 06:13 PM
Doberstein Stephen KSVP & Chief Scientific OfficerNov 16Sale38.254,524173,04378,734Nov 19 06:11 PM
Lingnau LutzDirectorSep 20Sale56.989,000512,82018,450Sep 21 07:32 PM
Ajer Jeffrey RobertDirectorSep 20Sale56.766,750383,13015,750Sep 21 07:29 PM
CHESS ROBERTDirectorSep 19Sale56.814,500255,645269,723Sep 21 07:31 PM
GREER R SCOTTDirectorSep 04Option Exercise5.1410,00051,400140,333Sep 06 07:12 PM
GREER R SCOTTDirectorSep 04Sale67.3910,000673,900130,333Sep 06 07:12 PM
WINGER DENNIS LDirectorAug 21Option Exercise14.2615,000213,90057,750Aug 21 07:32 PM
WINGER DENNIS LDirectorAug 21Sale60.3015,000904,50042,750Aug 21 07:32 PM
WINGER DENNIS LDirectorAug 17Option Exercise14.2615,000213,90057,750Aug 21 07:32 PM
WINGER DENNIS LDirectorAug 17Sale59.6215,000894,30042,750Aug 21 07:32 PM
WINGER DENNIS LDirectorAug 14Sale60.1517,1251,030,06942,750Aug 15 07:30 PM
WINGER DENNIS LDirectorAug 13Sale61.0417,1251,045,31059,875Aug 15 07:30 PM
ROBIN HOWARD WPresident & CEOJun 27Option Exercise10.6943,333463,230267,689Jun 27 07:42 PM
ROBIN HOWARD WPresident & CEOJun 27Sale47.3943,3332,053,551224,356Jun 27 07:42 PM
ROBIN HOWARD WPresident & CEOJun 26Option Exercise10.6943,333463,230267,689Jun 27 07:42 PM
ROBIN HOWARD WPresident & CEOJun 26Sale49.3643,3332,138,917224,356Jun 27 07:42 PM
ROBIN HOWARD WPresident & CEOJun 25Option Exercise10.6943,334463,240267,690Jun 27 07:42 PM
ROBIN HOWARD WPresident & CEOJun 25Sale51.8243,3342,245,568224,356Jun 27 07:42 PM
GREER R SCOTTDirectorJun 06Option Exercise5.148,60044,204138,933Jun 06 07:42 PM
WHITFIELD ROY ADirectorJun 06Buy59.373,400201,860177,000Jun 07 07:40 PM
GREER R SCOTTDirectorJun 06Sale60.008,600516,000130,333Jun 06 07:42 PM
CHESS ROBERTDirectorJun 05Option Exercise14.2610,000142,600284,223Jun 07 07:39 PM
WHITFIELD ROY ADirectorJun 05Buy55.221,60088,352173,600Jun 07 07:40 PM
CHESS ROBERTDirectorJun 05Sale55.1610,000551,600274,223Jun 07 07:39 PM
GREER R SCOTTDirectorJun 04Option Exercise5.141,4007,196131,733Jun 06 07:42 PM
GREER R SCOTTDirectorJun 04Sale61.991,40086,786130,333Jun 06 07:42 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerMay 16Sale83.393,576298,20365,281May 18 07:07 PM
Hora ManinderSVP Pharma Dev & Mfg OpsMay 16Sale83.394,060338,56376,201May 18 07:02 PM
Nicholson JohnSVP & Chief Operating OfficerMay 16Sale83.394,917410,029162,596May 18 07:05 PM
Labrucherie Gil MSVP & Chief Financial OfficerMay 16Sale83.394,941412,03094,798May 18 07:03 PM
Doberstein Stephen KSVP & Chief Scientific OfficerMay 16Sale83.393,435286,44563,959May 18 07:01 PM
ROBIN HOWARD WPresident & CEOMay 16Sale83.3912,7911,066,641224,356May 18 07:06 PM
Labrucherie Gil MSVP & Chief Financial OfficerMay 03Option Exercise10.6930,000320,700129,739May 03 08:43 PM
ROBIN HOWARD WPresident & CEOMay 03Option Exercise10.6943,333463,230280,480May 03 08:42 PM
CHESS ROBERTDirectorMay 03Option Exercise8.7925,000219,700289,223May 04 06:55 PM
ROBIN HOWARD WPresident & CEOMay 03Sale82.8643,3333,590,572237,147May 03 08:42 PM
Labrucherie Gil MSVP & Chief Financial OfficerMay 03Sale82.8630,0002,485,80099,739May 03 08:43 PM
CHESS ROBERTDirectorMay 03Sale82.8025,0002,070,050274,223May 04 06:55 PM
ROBIN HOWARD WPresident & CEOMay 02Option Exercise10.6943,333463,230280,480May 03 08:42 PM
Labrucherie Gil MSVP & Chief Financial OfficerMay 02Option Exercise10.6930,000320,700129,739May 03 08:43 PM
Labrucherie Gil MSVP & Chief Financial OfficerMay 02Sale85.6330,0002,568,90099,739May 03 08:43 PM
ROBIN HOWARD WPresident & CEOMay 02Sale85.6343,3333,710,605237,147May 03 08:42 PM
Labrucherie Gil MSVP & Chief Financial OfficerMay 01Option Exercise10.6930,000320,700129,739May 03 08:43 PM
ROBIN HOWARD WPresident & CEOMay 01Option Exercise10.6943,334463,240280,481May 03 08:42 PM
ROBIN HOWARD WPresident & CEOMay 01Sale83.6543,3343,624,889237,147May 03 08:42 PM
Labrucherie Gil MSVP & Chief Financial OfficerMay 01Sale83.6530,0002,509,50099,739May 03 08:43 PM
WHITFIELD ROY ADirectorApr 17Option Exercise14.2630,000427,800172,000Apr 18 06:05 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerApr 16Option Exercise10.6913,881148,38882,738Apr 18 06:03 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerApr 16Sale101.4613,8811,408,36668,857Apr 18 06:03 PM
Hora ManinderSVP Pharma Dev & Mfg OpsApr 10Option Exercise7.215023,61980,763Apr 12 06:05 PM
Hora ManinderSVP Pharma Dev & Mfg OpsApr 10Sale105.6750253,04680,261Apr 12 06:05 PM
Doberstein Stephen KSVP & Chief Scientific OfficerApr 09Option Exercise7.2149,500356,895116,894Apr 09 08:21 PM
Hora ManinderSVP Pharma Dev & Mfg OpsApr 09Option Exercise7.219,49868,48189,759Apr 09 08:22 PM
Doberstein Stephen KSVP & Chief Scientific OfficerApr 09Sale96.1349,5004,758,43567,394Apr 09 08:21 PM
Hora ManinderSVP Pharma Dev & Mfg OpsApr 09Sale105.059,498997,76580,261Apr 09 08:22 PM
GREER R SCOTTDirectorApr 06Option Exercise14.2630,000427,800160,333Apr 09 08:22 PM
CHESS ROBERTDirectorApr 06Option Exercise8.7925,000219,700289,223Apr 09 08:20 PM
Doberstein Stephen KSVP & Chief Scientific OfficerApr 06Option Exercise9.10110,5001,005,505177,894Apr 09 08:21 PM
Doberstein Stephen KSVP & Chief Scientific OfficerApr 06Sale91.69110,50010,131,74567,394Apr 09 08:21 PM
GREER R SCOTTDirectorApr 06Sale92.2230,0002,766,600130,333Apr 09 08:22 PM
CHESS ROBERTDirectorApr 06Sale92.1425,0002,303,600274,223Apr 09 08:20 PM
Hora ManinderSVP Pharma Dev & Mfg OpsApr 05Option Exercise7.2120,000144,200100,261Apr 09 08:22 PM
Lingnau LutzDirectorApr 05Option Exercise9.2430,000277,20057,450Apr 09 08:23 PM
Lingnau LutzDirectorApr 05Sale101.7430,0003,052,20027,450Apr 09 08:23 PM
Hora ManinderSVP Pharma Dev & Mfg OpsApr 05Sale101.7520,0002,035,00080,261Apr 09 08:22 PM
KUEBLER CHRISTOPHER ADirectorMar 07Option Exercise6.2437,400233,23677,900Mar 08 06:10 PM
KUEBLER CHRISTOPHER ADirectorMar 07Sale97.4137,4003,643,13440,500Mar 08 06:10 PM
Nicholson JohnSVP & Chief Operating OfficerMar 07Sale100.45100,14410,059,465167,513Mar 08 06:09 PM
KUEBLER CHRISTOPHER ADirectorMar 06Option Exercise5.142,60013,36443,100Mar 08 06:10 PM
KUEBLER CHRISTOPHER ADirectorMar 06Sale100.302,600260,78040,500Mar 08 06:10 PM
Nicholson JohnSVP & Chief Operating OfficerMar 06Sale98.29120,00011,794,800267,657Mar 08 06:09 PM
ROBIN HOWARD WPresident & CEOFeb 16Sale82.9412,7881,060,637237,147Feb 20 07:10 PM
Doberstein Stephen KSVP & Chief Scientific OfficerFeb 16Sale82.942,426201,21267,394Feb 20 07:07 PM
Hora ManinderSVP Pharma Dev & Mfg OpsFeb 16Sale82.942,875238,45380,261Feb 20 07:07 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerFeb 16Sale82.942,545211,08268,857Feb 20 07:10 PM
Nicholson JohnSVP & Chief Operating OfficerFeb 16Sale82.944,879404,664387,657Feb 20 07:09 PM
Labrucherie Gil MSVP & Chief Financial OfficerFeb 16Sale82.943,477288,38299,739Feb 20 07:08 PM